cma

Cridanimod (10-carboxymethyl-9-acridanone, CMA) is a potent STING agonist that directly binds to STING and triggers a strong antiviral response through the TBK1 IRF3 route.

Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

BCMA72-80 acetate is a HLA-A2 specific B cell maturation antigen (BCMA) peptide. It is used to study multiple myeloma and tumors, which expresses B cell maturation antigen.

PACMA 31 is an irreversible and covalent inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. PACMA 31 significantly suppresses ovarian tumor growth and exhibits tumor targeting ability.

Epacmarstobart (FSI-189; GS-0189) is a chimeric humanized IgG1κ antibody targeting mouse Signal Regulatory Protein Alpha (SIRPA).

BCMA72-80 is an HLA-A2-specific B-cell maturation antigen (BCMA) peptide with a strong affinity for HLA-A2, and is employed in research on multiple myeloma or other tumors expressing B-cell maturation antigen.

QX77 is a chaperone-mediated autophagy (CMA) activator.

AR7 is a retinoic acid receptor α (RARα) antagonist.

CA77.1(CA) is a novel chaperon-mediated autophagy (CMA) activator for the treatment of Alzheimer's disease (AD).

Epimedokoreanin B (EKB), an isoprenylated flavonoid isolated from Korean Epimedium, exhibited anticancer activity in human non-small cell lung cancer (NSCLC) A549 and NCI-H292 cells.Epimedokoreanin B also possesses anti-inflammatory and antibacterial activities, and may have scavenging activity against DPPH radicals, inhibiting the proliferation of MCF-7 and HepG2 in a dose-dependent manner. Epimedokoreanin B also exhibits anti-inflammatory and antibacterial activity, with DPPH radical scavenging activity, and inhibits the proliferation of MCF-7 and HepG2 in a dose-dependent manner.Epimedokoreanin B significantly inhibits the formation of N (α)-(carboxymethyl)lysine (CML) and N (Ï)-(carboxymethyl)arginine (CMA), and prevents clinical complications of diabetes mellitus through the inhibition of advanced glycation end-products (AGEs).

Ac2-26 ammonium, an N-terminal peptide of annexin 1, exhibits anti-inflammatory properties, reduces IKKβ protein levels in lysosomes via chaperone-mediated autophagy (CMA), improves lung ischemia-reperfusion injury outcomes, and mitigates airway inflammation and hyperresponsiveness in an asthma rat model [1] [2] [3] [4].